Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
The combination of KN046 and KN026, as a chemo-free regimen, demonstrated favorable clinical efficacy with comparative toxicities in pretreated patients with advanced HER2-positive breast cancer.
Authors
- Yaping Yang (ORCID: https://orcid.org/0000-0001-7158-8807)
- Rusen Zhao
- Chengyang Song (ORCID: https://orcid.org/0009-0008-0749-568X)
- Xujuan Wang
- Hongwei Yang (ORCID: https://orcid.org/0009-0006-8788-3230)
- Lin Shen (ORCID: https://orcid.org/0000-0002-8798-4756)
- Xiangcai Wang (ORCID: https://orcid.org/0000-0002-7162-0552)
- Lei Chen (ORCID: https://orcid.org/0000-0003-4863-4363)
- Jieqiong Liu (ORCID: https://orcid.org/0000-0001-7859-3764)
- Mingli Ni
- Ting Xu (ORCID: https://orcid.org/0000-0002-0172-9683)
Institutions
- Fujian Medical University (CN)
- Sun Yat-sen University (CN)
- Peking University (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Peking University Cancer Hospital (CN)
- Suizhou Central Hospital (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Ningbo No. 2 Hospital (CN)
- Neijiang Normal University (CN)
- Luoyang Central Hospital Affiliated to Zhengzhou University (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- Xian Yang Central Hospital (CN)
- Ministry of Education (ET)
- Central Hospital of Zibo (CN)
- Union Hospital (US)
- Union Hospital (CN)
- Alps Electric (Japan) (JP)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3888
- Citations
- 5
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- National Natural Science Foundation of China
- University of Texas MD Anderson Cancer Center